REG - Genus - AGM Trading Update

GenusAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251119:nRSS0525Ia&default-theme=true

RNS Number : 0525I  Genus PLC  19 November 2025

19 November 2025

Genus plc ("Genus" or the "Group")

AGM Trading Update - Strong start to the year

Genus (LSE: GNS), a leading global animal genetics company, publishes the
following unaudited trading update for the four months ending 31 October 2025
to coincide with its AGM at 11:00am GMT this morning.

Genus has had a strong start to the year and the Board expects Group FY26
adjusted profit before tax to be modestly ahead of the midpoint of current
market expectations(1).

PIC trading continued to be strong with every region achieving royalty revenue
and adjusted operating profit growth(2). PIC performed particularly well in
China with strong royalty revenue growth being a key driver.

ABS adjusted operating profit(2) has been slightly lower than expected due to
phasing. Management expects a step up in performance in the second half. Value
Acceleration Programme Phase 3 initiatives are progressing as planned.

Genus will announce its interim results for the six month period from 1 July
2025 to 31 December 2025 on 26 February 2026.

Jorgen Kokke, CEO of Genus, said:

"Genus has made a strong start to the year with PIC continuing to demonstrate
its robust growth model. ABS profit performance has been slightly lower than
expected but we expect stronger performance in the second half. We look
forward to the rest of the year with confidence."

For further information please contact:

Genus plc      Tel: +44 (0)1256 345 970

Jorgen Kokke, Chief Executive Officer

Andy Russell, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan    Tel: +44 (0)207 466 5000

Charles Ryland; Mark Court; Toto Berger; Jamie Hooper

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network. The PRRS Resistant Pig is a market leading innovation in gene
editing, which Genus is looking to commercialise in the porcine industry once
regulatory approval is gained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Footnotes

(1) The Company compiled consensus estimate range for Group FY26 actual
currency adjusted profit before tax is £77.6m to £85.0m with an average
midpoint of £80.5m, and is based upon 8 analyst estimates. These forecasts
exclude any impact from the Chinese porcine joint venture formation announced
on 4 September 2025.

(2) In constant currency

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFEFMAEISEIF



            Copyright 2019 Regulatory News Service, all rights reserved